This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, X. Articles by Frenkel, K. Search for Related Content PubMed PubMed Citation Articles by Li, X. Articles by Frenkel, K.

Interleukin-1 Up-Regulation in Vivo by a Potent Carcinogen 7,12-Dimethylbenz(a)anthracene (DMBA) and Control of DMBA-induced Inflammatory Responses¹

Department of Environmental Medicine, New York University School of Medicine [X. L., J. E., R. S., C. M., K. F.], and Kaplan Comprehensive Cancer Center [K. F.], New York, New York 10016

Tumor-initiating properties of complete carcinogens such as 7,12-dimethylbenz(a)anthracene (DMBA) are well known but not the mechanism of DMBA-mediated tumor promotion. Our hypothesis is that interleukin (IL)-1, an early proinflammatory cytokine that initiates a cascade of other cytokines and growth factors, is up-regulated by DMBA and contributes to inflammation and carcinogenesis. We found that topical exposure of SENCAR mice to a carcinogenic DMBA dose indeed triggers significant increases in mouse skin IL-1 and IL-1 mRNA. Five DMBA applications (200 nmol each) caused a statistically significant (P = 0.02) increase in serum IL-1, comparable with that induced by 12-O-tetradecanoylphorbol-13-acetate, a potent tumor promoter. IL-1 increase in serum was evident 24 h after the first DMBA application, whereas that in skin required five DMBA doses and became statistically significant (P < 0.0003) 48 h later. Skin IL-1 enhancement was preceded by a 6-fold up-regulation of IL-1 mRNA. A pretreatment with antimurine IL-1 antibody (Ab) nearly abolished DMBA-induced IL-1 mRNA (P = 0.0001) in skin and substantially decreased IL-1 in serum. Infiltration of polymorphonuclear leukocytes into skin was elevated 6-fold (P = 0.002) and >10-fold (P = 0.001) 24 h and 48 h after the fifth DMBA exposure, respectively. A pretreatment with anti-IL-1 Ab decreased polymorphonuclear leukocyte infiltration by >65% (P < 0.02), which suggests that this process is at least 65% under IL-1 control. Anti-IL-1 antibodies had no effect on edema, thus dissociating the two inflammation markers. Injecting anti-IL-1 Ab before DMBA applications significantly (P < 0.04) decreased the volume of carcinomas (CAs) in comparison with CAs that arose in mouse skin injected with a nonspecific serum. These results prove that IL-1 is induced by a carcinogenic DMBA dose and contributes to DMBA-induced inflammation and volume of CAs, hallmarks of tumor promotion and progression.

This article has been cited by other articles:

				J. B. Swann, M. D. Vesely, A. Silva, J. Sharkey, S. Akira, R. D. Schreiber, and M. J. Smyth Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis PNAS, January 15, 2008; 105(2): 652 - 656. [Abstract] [Full Text] [PDF]

				S. Ikuta, H. Edamatsu, M. Li, L. Hu, and T. Kataoka Crucial Role of Phospholipase C{varepsilon} in Skin Inflammation Induced by Tumor-Promoting Phorbol Ester Cancer Res., January 1, 2008; 68(1): 64 - 72. [Abstract] [Full Text] [PDF]

				V. Ablamunits, Y. Cohen, I. B. Brazee, H. P. Gaetz, C. Vinson, and S. Klebanov Susceptibility to Induced and Spontaneous Carcinogenesis Is Increased in Fatless A-ZIP/F-1 but not in Obese ob/ob Mice. Cancer Res., September 1, 2006; 66(17): 8897 - 8902. [Abstract] [Full Text] [PDF]